- Home
- INZY vs CTSO Comparison
INZY vs CTSO Comparison
Compare INZY & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- CTSO
- Stock Information
- Founded
- INZY 2015
- CTSO 1997
- Country
- INZY United States
- CTSO United States
- Employees
- INZY N/A
- CTSO N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- CTSO Medical/Dental Instruments
- Sector
- INZY Health Care
- CTSO Health Care
- Exchange
- INZY Nasdaq
- CTSO Nasdaq
- Market Cap
- INZY 64.9M
- CTSO 61.3M
- IPO Year
- INZY 2020
- CTSO N/A
- Fundamental
- Price
- INZY $0.91
- CTSO $1.00
- Analyst Decision
- INZY Strong Buy
- CTSO Strong Buy
- Analyst Count
- INZY 10
- CTSO 3
- Target Price
- INZY $16.90
- CTSO $4.67
- AVG Volume (30 Days)
- INZY 517.6K
- CTSO 85.6K
- Earning Date
- INZY 03-10-2025
- CTSO 05-08-2025
- Dividend Yield
- INZY N/A
- CTSO N/A
- EPS Growth
- INZY N/A
- CTSO N/A
- EPS
- INZY N/A
- CTSO N/A
- Revenue
- INZY N/A
- CTSO $37,739,531.00
- Revenue This Year
- INZY N/A
- CTSO $9.20
- Revenue Next Year
- INZY N/A
- CTSO $11.64
- P/E Ratio
- INZY N/A
- CTSO N/A
- Revenue Growth
- INZY N/A
- CTSO 1.80
- 52 Week Low
- INZY $0.88
- CTSO $0.70
- 52 Week High
- INZY $7.80
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- INZY 32.10
- CTSO 44.01
- Support Level
- INZY $0.94
- CTSO $0.97
- Resistance Level
- INZY $1.03
- CTSO $1.08
- Average True Range (ATR)
- INZY 0.08
- CTSO 0.08
- MACD
- INZY 0.01
- CTSO -0.01
- Stochastic Oscillator
- INZY 13.64
- CTSO 17.53
About INZY Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.